拓扑异构酶 I 抑制剂与耐药性。
Topoisomerase I inhibitors and drug resistance.
机构信息
Division of Hematology-Oncology, The Barbara Ann Karmanos Cancer Institute, Wayne State University, 3900 John R., Detroit, MI, U.S.A.
出版信息
Cytotechnology. 1998 Sep;27(1-3):149-64. doi: 10.1023/A:1008008719699.
Abstract
DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics. As many tumors can acquire resistance to drug treatment and become refractary to the chemotherapy it is very important to investigate the mechanisms involved in such a drug resistance for circumventing the phenomenon. This article describes the role of topoisomerase I in cell functions and the methods used to assess its in vitro catalytic activity. It reviews the mechanisms of cytotoxicity of the most specific antitopoisomerase I drugs by considering also the phenomenon of drug resistance. Some factors useful to drive the future perspectives in the development of new topoisomerase I inhibitors are also evidenced and discussed.
摘要
DNA 拓扑异构酶 I 是一种核酶，通过在 DNA 分子中引入单链断裂来催化 DNA 拓扑结构的转换。该酶代表了一种新型的、独特的分子靶点，通过属于喜树碱类抗肿瘤药物的抗拓扑异构酶药物进行癌症治疗。由于许多肿瘤可以对药物治疗产生耐药性，并对化疗产生抗药性，因此研究这种耐药性涉及的机制以避免这种现象非常重要。本文描述了拓扑异构酶 I 在细胞功能中的作用，以及用于评估其体外催化活性的方法。它还考虑了耐药性现象，综述了最特异的抗拓扑异构酶 I 药物的细胞毒性机制。还提出和讨论了一些有助于推动新型拓扑异构酶 I 抑制剂开发的未来展望的因素。
相似文献
1
Topoisomerase I inhibitors and drug resistance.拓扑异构酶 I 抑制剂与耐药性。
Cytotechnology. 1998 Sep;27(1-3):149-64. doi: 10.1023/A:1008008719699.
2
DNA topoisomerase targeting drugs: mechanisms of action and perspectives.靶向DNA拓扑异构酶的药物：作用机制与展望
Anticancer Drugs. 1997 Oct;8(9):811-22. doi: 10.1097/00001813-199710000-00001.
3
4
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.将DNA拓扑异构酶II毒素（依托泊苷、clerocidin）和催化抑制剂（阿柔比星、ICRF-187）映射到拓扑异构酶II催化循环的四个不同步骤。
Biochem Pharmacol. 1996 Apr 12;51(7):879-86. doi: 10.1016/0006-2952(95)02241-4.
5
DNA-topoisomerase inhibitors.DNA拓扑异构酶抑制剂
Curr Opin Oncol. 1993 Nov;5(6):1023-8.
6
Topoisomerase I in multiple drug resistance.多药耐药中的拓扑异构酶I
Cytotechnology. 1993;12(1-3):127-35. doi: 10.1007/BF00744661.
7
High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.人表皮角质形成细胞（HaCaT）对拓扑异构酶抑制剂高度敏感。
Cell Prolif. 2001 Aug;34(4):243-52. doi: 10.1046/j.0960-7722.2001.00214.x.
8
DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.DNA 拓扑异构酶 II 酶作为癌症化疗的分子靶点。
Curr Cancer Drug Targets. 2010 Nov;10(7):758-71. doi: 10.2174/156800910793605785.
9
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs.新型细菌拓扑异构酶抑制剂：酰胺酶结合基序对三环类似物的独特靶向活性。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048223. doi: 10.1128/aac.00482-23. Epub 2023 Sep 19.
10
Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.近年来，双重拓扑异构酶 I 和 II 抑制剂作为抗癌药物的发展取得了进展。
Curr Med Chem. 2010;17(35):4270-90. doi: 10.2174/092986710793361252.
引用本文的文献
1
Structural modifications of berberine and their binding effects towards polymorphic deoxyribonucleic acid structures: A review.小檗碱的结构修饰及其对多态性脱氧核糖核酸结构的结合作用：综述
Front Pharmacol. 2022 Aug 9;13:940282. doi: 10.3389/fphar.2022.940282. eCollection 2022.
2
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.DNA损伤反应通路中的基因组、转录组和功能改变作为卵巢癌化疗反应的潜在生物标志物
Cancers (Basel). 2021 Mar 20;13(6):1420. doi: 10.3390/cancers13061420.
3
Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.用载伊立替康纳米脂质体打破光免疫偶联物的选择性摄取权衡，实现协同的多靶点癌症靶向治疗。
J Nanobiotechnology. 2020 Jan 2;18(1):1. doi: 10.1186/s12951-019-0560-5.
4
Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model.在结肠癌模型中，用 DNA 损伤诱导剂 CPT 处理时，细胞骨架中间丝蛋白 vimentin 在早期凋亡癌细胞中的激活启动了存活途径。
Cell Death Dis. 2019 Jun 13;10(6):467. doi: 10.1038/s41419-019-1690-2.
5
Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.半合成穿心莲内酯类似物对哺乳动物细胞拓扑异构酶 IIα 的抑制作用和诱导凋亡。
Invest New Drugs. 2013 Apr;31(2):320-32. doi: 10.1007/s10637-012-9868-9. Epub 2012 Aug 17.
6
High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.人表皮角质形成细胞（HaCaT）对拓扑异构酶抑制剂高度敏感。
Cell Prolif. 2001 Aug;34(4):243-52. doi: 10.1046/j.0960-7722.2001.00214.x.
本文引用的文献
1
Topoisomerase I inhibitors: review and update.拓扑异构酶I抑制剂：综述与更新。
Ann Oncol. 1997 Sep;8(9):837-55. doi: 10.1023/a:1008270717294.
2
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.临床重要喜树碱衍生物在P-糖蛋白过表达细胞系中的差异细胞毒性。
Cancer Chemother Pharmacol. 1997;40(5):433-8. doi: 10.1007/s002800050682.
3
Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.新型7-烷基亚甲二氧基喜树碱衍生物表现出增强的细胞毒性，并且在与纯化的哺乳动物拓扑异构酶I以及在人结肠癌SW620细胞中均诱导形成持续的可裂解复合物。
Mol Pharmacol. 1997 Jul;52(1):82-7. doi: 10.1124/mol.52.1.82.
4
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.稠合四环喹啉和喹喔啉的N-[2-(二甲基氨基)乙基]羧酰胺衍生物的合成及其抗肿瘤特性：一类新型的潜在拓扑异构酶抑制剂
J Med Chem. 1997 Jun 20;40(13):2040-6. doi: 10.1021/jm970044r.
5
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.混合拓扑异构酶I/II抑制剂N-[2-(二甲基氨基)乙基]吖啶-4-甲酰胺的吖啶取代类似物的构效关系
J Med Chem. 1997 Jun 6;40(12):1919-29. doi: 10.1021/jm970004n.
6
Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.20-(S)-喜树碱类似物作为DNA拓扑异构酶I抑制剂和抗癌/抗肿瘤药物的比较分子场分析及分子建模研究
J Comput Aided Mol Des. 1997 Jan;11(1):71-8. doi: 10.1023/a:1008027528218.
7
Analysis of expression and function of topoisomerase I and II during meiosis in male mice.雄性小鼠减数分裂过程中拓扑异构酶I和II的表达及功能分析
Mol Reprod Dev. 1997 Apr;46(4):489-98. doi: 10.1002/(SICI)1098-2795(199704)46:4<489::AID-MRD7>3.0.CO;2-K.
8
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.七种耐药小细胞肺癌细胞系的体外交叉耐药性和协同敏感性：多西他赛、紫杉醇、拓扑替康和吉西他滨合适联合用药伙伴的临床前鉴定
Br J Cancer. 1997;75(6):869-77. doi: 10.1038/bjc.1997.154.
9
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.喜树碱、拓扑替康和9-氨基喜树碱对人、犬和鼠骨髓祖细胞（CFU-GM）的体外差异毒性。
Cancer Chemother Pharmacol. 1997;39(5):467-72. doi: 10.1007/s002800050600.
10
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.喜树碱衍生物CPT-11的代谢产物SN-38对多药耐药的人胶质母细胞瘤细胞凋亡的诱导作用
Cancer Chemother Pharmacol. 1997;39(5):417-23. doi: 10.1007/s002800050592.
Zotero 插件